Dr. David Kwiatkowski, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Massachusetts General Hospital

  Fellowship Hospital, 1984

• Massachusetts General Hospital

  Residency Hospital, 1982

• Massachusetts General Hospital

  Internship Hospital, 1980

• Columbia University Vagelos College Of Physicians And Surgeons

  Medical School, 1979

• English

• Creole

• French

• French Creole

• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium, 2014-10-01

• Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment, 2022-08-26

• Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells, 2017-08-04

• Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model, 2015-05-24

• An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers, 2015-08-10

• Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistentTSC1/TSC2biallelic inactivation, and noBRAFmutations, 2017-09-08

• Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors, 2020-04-22

• Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations from the 2015 Strategic Planning Conference, 2016-04-02

• Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma, 2016-04-23

• Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide, 2013-12-02

• Multilevel Genomics-based Taxonomy of Renal Cell Carcinoma, 2016-03-03

• Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value, 2013-04-04

• Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site inTSC1andTSC2, 2015-03-18

• Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period, 2022-01-15

• Renal Cell Carcinoma in Tuberous Sclerosis Complex, 2014-05-28

• MITFis a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation ofCYR61, 2020-10-20

• nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors, 2021-10-12

• MET IHC is a Poor Screen forMETAmplification orMETexon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium, 2019-06-20

• Notch transactivates Rheb to maintain the multipotency of TSC-null cells, 2017-11-29

• The introduction of systematic genomic testing for patients with non-small cell lung cancer, 2012-10-19

• Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib, 2018-11-01

• Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance Pathologist Evaluation of MET Protein Expression, 2019-08-27

• MCL1 and DEDD promote urothelial carcinoma progression, 2019-02-18

• Multiple Novel Loci, Including Those Related to Crohn's Disease, Psoriasis and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17,686 Women: the Women's Genome Health Study, 2009-02-12

• Tuberous Sclerosis Complex Activity is Required to Control Neuronal Stress Responses in an mTOR-Dependent Manner, 2009-05-06

• Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice, 2010-10-12

• Prediction of Neurodevelopment in Infants With Tuberous Sclerosis Complex Using Early EEG Characteristics, 2020-10-16

• Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways, 2011-07-06

• Genetic loci associated with plasma concentration of LDL-C, HDL-C, triglycerides, ApoA1, and ApoB among 6382 Caucasian women in genome-wide analysis with replication, 2009-01-06

• Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example, 2010-10-12

• Ultra deep sequencing detects a low rate of mosaic mutations in Tuberous Sclerosis Complex, 2010-02-18

• Generalised mosaicism forTSC2mutation in isolated lymphangioleiomyomatosis, 2019-10-10

• Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2, and KRAS demonstrates that small second hit mutations in these genes are rare events, 2010-07-13

• Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations, 2021-03-16

• Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise, 2015-10-15

• Stochastic Model ofTsc1Lesions in Mouse Brain, 2013-05-16

• Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma, 2017-08-01

• Mosaic and Intronic Mutations inTSC1/TSC2Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing, 2015-11-05

• Integrative Molecular Characterization of Malignant Pleural Mesothelioma, 2018-10-15

• Chronic Activation of mTOR Complex 1 is Sufficient to Cause Hepatocellular Carcinoma, 2012-03-27

• TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity, 2009-12-07

• Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway, 2021-02-02

• Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer, 2021-04-23

• Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis, 2014-10-27

• Phenotypic distinctions between mosaic forms of tuberous sclerosis complex, 2019-05-22

• Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience, 2015-04-21

• FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma, 2021-11-10

• Epigenomic charting and functional annotation of risk loci in renal cell carcinoma, 2023-01-21

• Author Correction: Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment, 2022-09-14

• Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC), 2012-02-21

• FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis, 2010-11-16

• miRNAs and isomiRs: Serum-Based Biomarkers for the Development of Intellectual Disability and Autism Spectrum Disorder in Tuberous Sclerosis Complex, 2022-07-29

• Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias, 2017-12-26

• Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates, 2012-09-21

• Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex, 2022-05-16

• mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?, 2014-12-26

• Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma, 2016-02-01

• An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice, 2012-09-04

• mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion, 2023-03-03

• Angiomyolipoma Have Common Mutations in TSC2 but No Other Common Genetic Events, 2011-09-16

• Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment, 2017-08-14

• Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex? R. Moaveroet al., 2020-07-23

• SomaticERCC2Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors, 2016-04-25

• Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes:EGFRas an Example, 2010-10-12

• Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target, 2014-10-27

• A Vascular Model of Tsc1 Deficiency Accelerates Renal Tumor Formation with Accompanying Hemangiosarcomas, 2014-12-29

• Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases, 2018-02-09

• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial, 2022-09-12

• Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, 2016-05-09

• A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations, 2017-05-18

• Coordinated regulation of protein synthesis and degradation by mTORC1, 2014-07-13

• Whole Exome Sequencing IdentifiesTSC1/TSC2Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development, 2016-08-05

• TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1, 2012-07-12

• The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2), 2017-12-07

• Perivascular Epithelioid Cell Tumors (PEComas) HarboringTFE3Gene Rearrangements Lack theTSC2Alterations Characteristic of Conventional PEComas: Further Evidence for a Biologic Distinction, 2012-02-17

• Three independent mutations in theTSC2gene in a family with tuberous sclerosis, 2009-03-04

• Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer, 2020-08-31

• Targeted Deletion ofTsc1Causes Fatal Cardiomyocyte Hyperplasia Independently of Afterload, 2014-11-07

• Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes to immune checkpoint inhibitors, 2022-09-29

• SomaticLKB1Mutations Promote Cervical Cancer Progression, 2009-04-02

• Nipple angiofibromas with loss ofTSC2are associated with tuberous sclerosis complex, 2015-12-10

• Human pluripotent stem cell-derivedTSC2-haploinsufficient smooth muscle cells recapitulate features of Lymphangioleiomyomatosis, 2017-08-22

• Comprehensive molecular characterization of muscle invasive bladder cancer, 2017-10-05

• Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology, 2022-04-15

• The codon 72TP53polymorphism contributes to TSC-tumorigenesis through the Notch-Nodal axis., 2019-05-14

• Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study, 2019-06-03

• Renal and liver tumors inTsc2+/-mice, a model of Tuberous Sclerosis Complex, do not respond to treatment with atorvastatin, an HMG CoEnzyme A reductase inhibitor, 2009-07-07

• Genomic activation ofPPARGreveals a candidate therapeutic axis in bladder cancer, 2017-09-18

• Tsc1-Tp53loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma, 2013-07-15

• mTOR Pathway Mutations Cause Hemimegalencephaly and Focal Cortical Dysplasia, 2015-02-26

• CDKN2AAlterations and Response to Immunotherapy in Solid Tumors, 2021-06-01

• A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma, 2019-12-20

• Therapeutic targeting of DGKA-mediated macropinocytosis leads to phospholipid reprogramming in Tuberous Sclerosis Complex, 2021-02-16

• Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma, 2018-09-26

• mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability, 2017-10-19

• Comprehensive genomic profiling of metastatic tumors in a phase II biomarker study of everolimus in advanced renal cell carcinoma, 2018-04-25

• Amplification ofEGFRT790M causes resistance to an irreversible EGFR inhibitor, 2010-02-01

• mTORC1-S6K Activation by Endotoxin Contributes to Cytokine Up-Regulation and Early Lethality in Animals, 2010-12-21

• CDH1germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer, 2021-12-23

• Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase, 2015-07-30

• Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex, 2016-12-01

• Lkb1inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2, 2017-04-07

• Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile, 2020-10-13

• Molecular dissection of AKT activation in lung cancer cell lines, 2013-01-14